Exosome-Coated 5-Epitope KRAS mRNA Vaccine Disrupts Pancreatic Cancer Immune Barrier
Background
Pancreatic ductal adenocarcinoma (PDAC) is a paradigmatic 'cold tumor' that rarely responds to immunotherapy, despite KRAS mutations being present in over 90% of patients. The dense stroma surrounding the tumor blocks antigen and immune cell access, while the immunosuppressive tumor microenvironment further impairs the function of infiltrating T cells. Despite immune checkpoint inhibitors transforming the treatment landscape for many cancers, PDAC has shown limited clinical benefit, reflecting these barriers.
KRAS mutant proteins are selectively expressed in cancer cells, making them attractive vaccine antigens. However, the composition and delivery of the antigen remain critical challenges. Traditional parallel-connected approaches, which mix multiple full-length mRNAs, include non-immunogenic sequences and do not guarantee efficient co-expression of each antigen in the same cell. Lipid nanoparticles (LNPs), while widely used, often distribute to the liver rather than concentrating in lymph nodes and dendritic cells, where immune responses are initiated.
To overcome these bottlenecks, the research team developed a nano-vaccine that combines epitope-condensed mRNA with dendritic cell-derived exosomes, reengineering both antigen design and lymph node delivery.
Key Findings
The researchers designed a series-connected (SC) mRNA that sequentially arranges five immunodominant KRAS mutant epitopes (G12D, G12V, G12R, and two others) within a single open reading frame. This approach reduces non-productive sequences and enhances epitope presentation efficiency within the limited mRNA capacity, in contrast to parallel-connected (PC) mixtures of full-length transcripts.
As a delivery vehicle, they used β-sitosterol-based LNPs, which were further coated with exosomes derived from mature dendritic cells to create LNP@exo. The exosome coating was designed to confer lymph node tropism and intrinsic adjuvant activity. The resulting mKRAS SC-LNP@exo strongly activated dendritic cells in vitro and promoted the secretion of Th1 cytokines associated with cell-mediated immunity.
In vivo, the vaccine rapidly accumulated in lymph nodes after administration. In the Pan02 pancreatic cancer mouse model, it induced significantly greater CD8⁺ T cell infiltration into the tumor than control formulations. Most notably, one-third of the treated mice achieved complete tumor regression, with no observed off-target toxicity. The combination of antigen condensation and exosome coating not only enhanced antigen-presenting cell activation but also facilitated the formation of an immune response that led to tumor-killing T cell infiltration.
Implications and Outlook
This study highlights that the performance of mRNA cancer vaccines is not solely determined by antigen sequence but also by where they are delivered and which innate immune signals they encounter. In particular, the strategy of bundling multiple mutant epitopes into a single transcript offers the potential to broadly target diverse patient populations with KRAS mutations while reducing manufacturing complexity and unnecessary sequences. The exosome-coating strategy also shows promise for extension to other cancer vaccines requiring lymph node targeting.
However, the results are based on preclinical data from the Pan02 mouse model. The proportion of complete tumor regression observed in mice does not necessarily translate directly to human therapeutic outcomes. Variations in human leukocyte antigen (HLA) types and KRAS mutation combinations across patients must be evaluated to determine the breadth of epitope coverage. Additionally, challenges remain in scaling up the production of exosome-coated vaccines with consistent quality, standardizing the degree of exosome-LNP conjugation, and establishing safety, duration of immune response, and memory immunity against tumor rechallenge before clinical trials can proceed.
Pancreatic ductal adenocarcinoma (PDAC) is driven by KRAS mutations in over 90% of cases yet remains refractory to most therapies due to poor antigen delivery and a suppressive tumor microenvironment. To address these challenges, we developed an exosome‑augmented, epitope‑focused mRNA nanovaccine. First, we engineered a series-connected (SC) mRNA that condenses five immunodominant KRAS‑mutant epitopes (G12D, G12V, G12R and two other sequences) into a single open reading frame. This design minimizes non‑productive sequence and enhances antigen presentation compared to a conventional parallel-connected (PC) mixture of full‑length transcripts. Second, we cloaked β‑sitosterol LNPs with mature dendritic‑cell-derived exosomes (LNP@exo), endowing the particles with lymph‑node tropism and intrinsic adjuvanticity. The resulting mKRAS SC-LNP@exo triggered potent dendritic cell activation and Th1 cytokine release in vitro, rapidly accumulated in lymph nodes, and drove superior CD8⁺ T cell infiltration in a Pan02 tumor model. Remarkably, one‑third of mKRAS SC-LNP@exo treated mice achieved complete tumor regression without off‑target toxicity. These findings demonstrate that combining epitope‑condensed mRNA with exosome‑cloaked LNP delivery can convert "cold" KRAS‑mutant PDAC into an immunologically responsive tumor and provide a broadly applicable strategy for next‑generation mRNA cancer vaccines.
In clinical application, the vaccine may first be considered for patients with confirmed KRAS G12D, G12V, or G12R mutations via tumor genomic testing, used in combination with surgery or chemotherapy. For example, it could be administered to patients suspected of having microscopic residual disease after surgery to suppress the re-growth of KRAS-mutant cancer cells, or to tumors that have not responded to immune checkpoint inhibitors by promoting CD8⁺ T cell infiltration. From an industrial perspective, the vaccine may be developed as an off-the-shelf platform combining high-frequency mutant epitopes, rather than a fully personalized approach requiring the production of a new vaccine for each patient. However, the cell-line management of exosome raw materials, batch consistency, potency testing, and long-term storage criteria are expected to influence the speed of commercialization.